Marina Khan
LightNews LightNews
banner
marina-khan.bsky.social
Marina Khan
@marina-khan.bsky.social
410 followers 250 following 44 posts
Therapeutic Radiographer (RTT)
R&D Lead Radiotherapy
SABR Consortium committee member
Views are my own
Posts Replies Media Videos
Pinned
marina-khan.bsky.social
Marina Khan @marina-khan.bsky.social · Nov 25
I have created a Radiotherapy starter pack so all professionals working with radiotherapy can connect. So let me know if you would like to be added.

go.bsky.app/NxYvXFV
Reposted by Marina Khan
drjkyl.bsky.social
Effectiveness of Chemotherapy Plus Immunotherapy and Molecular Alterations in Advanced Biliary Tract Cancer: Real-World Evidence From a Single-Center Australian Cohort
@cancer-control.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#carcinoma #biomarkers #oncology #prognosis
November 21, 2025 at 7:09 PM
Reposted by Marina Khan
npca-natcan.bsky.social
📢 The NPCA State of the Nation Report 2025 is OUT!

Find the report, supplementary documents & provider results here www.natcan.org.uk/reports/npca...

@natcan-news.bsky.social @hqip.bsky.social @prostatecanceruk.bsky.social @alison-tree.bsky.social @nhsengland.bsky.social

Please share!
NPCA State of the Nation Report 2025 - National Cancer Audit Collaborating Centre
The aim of the National Prostate Cancer Audit (NPCA) is to evaluate the patterns of care and outcomes for patients with prostate cancer in England and Wales, and to support services to improve the qua...
www.natcan.org.uk
October 9, 2025 at 9:58 AM
Reposted by Marina Khan
estroradiotherapy.bsky.social
🗣️ New #ESTROWebinar! Management of SCLC in the Immunotherapy Era
🗓 5 Nov | 17:00–18:00 CET
Chaired by Prof Corinne Faivre-Finn & Dr Suraiya Dubash (UK)
💻 Live Q&A with experts!
More info & Registration here: 👉 bit.ly/3KAbjPB

#RadiationOncology #LungCancer #SCLC #Immunotherapy #Webinar
October 10, 2025 at 10:09 AM
Reposted by Marina Khan
estroradiotherapy.bsky.social
📢 The first-ever ESTRO Clinical Workshop is coming to Vienna | 12–13 Mar 2026! Spots are limited—don’t miss out.
📌 Submit your motivational statement by 22 Oct to secure your place.

💻 Apply now 👉 bit.ly/47wlj5G
#ESTROCLIN26 #ClinicalWorkshop #RadiationOncology
October 10, 2025 at 10:25 AM
Reposted by Marina Khan
btog.bsky.social
💡 Discover the latest in mutation-driven lung cancer research.
Session 4 with @ruthstraussfdn.bsky.social rings science, debate, and progress together.
📅 13 Nov | 📍 The View, London
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
October 9, 2025 at 9:00 AM
Reposted by Marina Khan
ukons.bsky.social
Calling all Young and Early Career Cancer Nurses (YECCN)

The YECCN MIG is currently looking for 1x MIG Chair, 1x secretary and 8x committee members.

If interested & under 35/working for <5yrs, please email by 5th October, a 300 word expression of interest to:

ukons@media1productions.co.uk

#YECCN
September 28, 2025 at 12:04 AM
Reposted by Marina Khan
ascocancer.bsky.social
Exciting news! We’ve launched ASCO Edge, an online oncology practice management educational series exclusively available to ASCO members.

Get started today: brnw.ch/21wVVu3
September 19, 2025 at 5:19 PM
Reposted by Marina Khan
joannekarma.bsky.social
Please check out this from We Own It.

weownit.org.uk/act-now/new-...
Say no to new PFI in our NHS - take action
The government’s new 10-Year Plan for Health is proposing to bring disastrous private finance deals back into our NHS.
weownit.org.uk
September 19, 2025 at 9:10 PM
Reposted by Marina Khan
oncodaily.bsky.social
Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC

@drewmoghanaki.bsky.social @gerryhanna.bsky.social

oncodaily.com/voices/drew-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #LungCancer
Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC - OncoDaily
Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC / cancer, Drew Moghanaki, Gerry Hanna, LS-SCLC, OncoDaily, Oncology
oncodaily.com
September 11, 2025 at 5:55 PM
Reposted by Marina Khan
estroradiotherapy.bsky.social
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the #radiotherapy delineation benchmark case procedure, published in the Green Journal.
👉 Read it before your patients: bit.ly/4fLoatJ
September 12, 2025 at 7:44 AM
Reposted by Marina Khan
drpeedell.bsky.social
New #radiotherapy innovations are being stifled by the tortuous commissioning process. Patients deserve better! #radonc #oncology #medtwitter
Postcode lottery for new cancer treatments, doctors warn - BBC News www.bbc.co.uk/news/article...
Postcode lottery for new cancer treatments, doctors warn
Experts say bureaucracy is
www.bbc.co.uk
September 11, 2025 at 7:55 AM
Reposted by Marina Khan
qol.eortc.org
📢 Attending #EAPM2025 this week?
Today, our @eortc.org #QualityofLife Group member Ines Rathgeber will report on the development of an e-learning course focusing on the use of EORTC PRO measures for quality of life assessment in clinical practice 👇

eapm.eu.com/2025-eapm-co...

#CancerResearch
September 11, 2025 at 9:05 AM
Reposted by Marina Khan
letswinpc.org
✅ Finished treatment or on maintenance for #PancreaticCancer? We’ve got resources to help.

Find tips on managing side effects, eating well, coping with scanxiety, and staying up to date on the latest research. https://bit.ly/4lX0owd #GuideToAction #LetsWinPC
Living With
You may be undergoing maintenance treatment or you may have completed treatment but you are still part of the pancreatic cancer community.
bit.ly
September 4, 2025 at 4:00 PM
Reposted by Marina Khan
oncodaily.bsky.social
One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day

oncodaily.com/insight/one-...

#Cancer #Oncology #OncoDaily #Health #Medicine
One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day - OncoDaily
One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day / cancer, Katie Wakeham, OncoDaily, Oncology, One Voice For Radiotherapy, radiation
oncodaily.com
August 10, 2025 at 6:09 PM
Reposted by Marina Khan
lcharlesworth.bsky.social
Putting Patients First: Transforming Cancer Diagnosis, Treatment and Care Through Patient-Centred Approaches.

In this guest editorial, we reflect on why meaningful progress & the delivery of high quality cancer care requires more than technical innovation

www.radiographyonline.com/article/S107...
Putting patients first: Transforming cancer diagnosis, treatment and care through patient-centred approaches
Delivering high quality care is at the forefront of the cancer agenda for professionals and policy makers alike. Whilst it is clear that drug development alongside technical innovations and advancemen...
www.radiographyonline.com
August 1, 2025 at 6:23 AM
Reposted by Marina Khan
btog.bsky.social
Today on #WorldLungCancerDay, we reaffirm our mission to support thoracic oncology professionals and advocate for equitable, world-class care for all patients.

Together, we strive to match the best survival rates globally. 💙
#WLCD2025 #LungCancerAwareness #LCSM #lungcancer
August 1, 2025 at 8:09 AM
Reposted by Marina Khan
giorgioseano.bsky.social
🧠 Why does glioblastoma always outsmart treatment? In our #Neuro-Oncology paper, we identified proneural-mesenchymal hybrid glioblastoma cells that are resistant to therapy and dependent on nuclear import. doi.org/10.1093/neuo...
Short walkthrough below. Let’s dive in! 🧵 (1/9)
#GBM, #BrainTumor
Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear. Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both proneural and mesenchymal markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population. Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies. Conclusion: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.
July 17, 2025 at 9:08 AM
Reposted by Marina Khan
lizoriordan.bsky.social
BREAKING NEWS

Scientists at the @icr-ctsu.bsky.social have discovered how to predict which ER+ HER2+ cancers have a higher risk of recurrence in just 2 weeks!

Breaking news - Breast Cancer Breakthrough! #breastcancer
youtube.com/shorts/3rYUU...
Breaking news - Breast Cancer Breakthrough! #breastcancer
YouTube video by Dr Liz O'Riordan
youtube.com
July 19, 2025 at 8:23 AM
Reposted by Marina Khan
to-lo.co.uk
important listen for all involved in #radiotherapy.

pca.st/episode/a767...
"Captain Kirk Forgot to put the Machine on Stun"
pca.st
July 19, 2025 at 1:32 PM
Reposted by Marina Khan
estroradiotherapy.bsky.social
✨Today is #BrachytherapyAwarenessDay, let's spotlight precision in cancer care.
🎯#Brachytherapy boosts survival, helps preserve function & QoL, yet remains underused.
📢 Oncology professionals:
✅ Raise awareness
✅ Support access
✅ Empower patients
👉https://bit.ly/4lwRdTL
July 17, 2025 at 7:34 AM
Reposted by Marina Khan
estroradiotherapy.bsky.social
At #ESTRO25, a heated debate unfolded: “CBCT-based fast adaptation workflows will supersede MR-Linac usage.”
💬 With strong arguments on both sides, the audience shifted from 72% in favour to a near 50/50 split by the end.
👉 bit.ly/3Iavy59
July 3, 2025 at 7:50 AM
Reposted by Marina Khan
estroradiotherapy.bsky.social
Congratulations to our journal TipsRO - Technical Innovations and Patient Support in Radiation Oncology for achieving its first Impact Factor of 2.8! A reflection of the quality and dedication of the editorial team, authors, and the entire #RTT community.
June 26, 2025 at 10:53 AM
Reposted by Marina Khan
pattydiezh.bsky.social
A really educational day. Big shoutout to Tom Rackley & Rebecca Muirhead for leading the event & superstars @alison-tree.bsky.social and Dione Lother for sharing their wisdom. Amazing practical insights from @aileenduffton.bsky.social @marina-khan.bsky.social Helen Grimes & Joe Flaherty. Congrats!
marina-khan.bsky.social Marina Khan @marina-khan.bsky.social · Jun 24
We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social
June 24, 2025 at 8:40 PM
marina-khan.bsky.social
We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social
June 24, 2025 at 8:33 PM
Reposted by Marina Khan
deeponco.bsky.social
Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology

@alison-tree.bsky.social @harshanigreen.bsky.social

Full-text link:
authors.elsevier.com/a/1lFrI3lXQo...
June 13, 2025 at 7:14 PM